The stock is a binary event play on the Phase 2b PLATEAU interim data in Q1 2027. With $27.6M cash and a ~$36M market cap, the company has runway to data readout. Monitor enrollment updates and any partnership announcements. The EPS beat is positive but immaterial for a pre-revenue biotech.
Price Chart
Executive Summary
Veru reported Q2 2026 net loss of $2.7M ($0.12/share), narrower than the $7.9M loss a year ago, driven by lower R&D and G&A expenses. The key catalyst is the ongoing Phase 2b PLATEAU trial for enobosarm + semaglutide, with interim data expected in Q1 2027. The EPS beat consensus by 8.8%, but the company remains pre-revenue with no approved products, making the stock a binary event play on clinical data.
Key Financial Metrics
Key Facts
- Q2 2026 net loss $2.7M ($0.12/share) vs $7.9M ($0.54/share) in Q2 2025
- EPS of -$0.26 beat consensus of -$0.28 by 8.8%
- Cash position $27.6M as of March 31, 2026, up from $15.8M at Sept 30, 2025
- Phase 2b PLATEAU trial for enobosarm + semaglutide actively enrolling; interim analysis expected Q1 2027
- Operating loss from continuing operations narrowed to $7.2M from $8.1M YoY
- No revenue reported; company is pre-commercial
Financial Impact
Net loss improved by $5.2M YoY; cash burn reduced; no revenue
Risk Factors
- Clinical trial failure or disappointing interim data could wipe out equity value
- Cash burn may require dilutive financing before data readout
- No approved products or revenue stream; entirely dependent on pipeline success
- Competition from larger players in GLP-1 combination therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293805 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Aug 10, 2026 11w ago | Press Release | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Jul 2, 2026 16w ago | 8-K / 424B5 | $3.06 $2.83 | ▲ +7.52% | ▲ +8.39% | $2.28 (+25.49%) |
Jun 4, 2026 20w ago | 8-K | $4.23 $3.40 | ▼ −19.62% | ▼ −17.02% | $2.28 (−46.10%) |
May 13, 2026 23w ago | 8-K | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
May 13, 2026 23w ago | Press Release | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers